Aerpio Pharmaceuticals, Inc. (ARPO) 10-Q Quarterly Report May 2019

On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2019

CINCINNATI—(BUSINESS WIRE) — Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the first quarter ended March 31, 2019, and provided a business update.

“Although the TIME-2b study of the Tie2 activator, AKB-9778, did not meet its primary endpoint in non-proliferative diabetic retinopathy (NPDR), we continue to be encouraged by pre-specified secondary endpoint data that suggest the potential for AKB-9778 to treat primary open-angle glaucoma (POAG) and possibly diabetic nephropathy,” said Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. “In the near-term, our top priority is the development of our topical drop formulation of AKB-9778 for POAG, for which we expect to begin a Phase 1b clinical trial this quarter, with data anticipated by the end of the year. Our glaucoma program, combined with our license with Gossamer Bio, Inc. for GB004, a hypoxia inducible factor (HIF)-1 alpha stabilizer in clinical development for inflammatory bowel disease, represent two promising clinical-stage programs, each with near-term milestones. Additionally, we have reduced our company expenses and are committed to moving forward in a capital-efficient manner. Based on our current development plans, we have sufficient capital to fund our operations through at least the second quarter of 2021.”

Recent Company Highlights and Upcoming Milestones

•

Announced top-line results of the TIME-2b clinical trial designed to evaluate the safety and efficacy of AKB-9778, a Tie2 activator, in NPDR; the study did not meet its primary endpoint; however, the study generated encouraging data in a number of prespecified, key secondary endpoints, including reductions in urine albumin-to-creatinine ratio (UACR), a measure of kidney function, suggesting potential utility as a treatment for diabetic nephropathy, and reductions in intraocular pressure (IOP), suggesting potential utility in open-angle glaucoma;

•

Presented encouraging preliminary IOP data from the Company’s TIME-2b study at the Association for Research in Vision and Ophthalmology Annual Meeting 2019; and,

The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Thursday, May 9, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1422142/000156459019017966/arpo-10q_20190331.htm

View differences made from one quarter to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aerpio Pharmaceuticals, Inc..

Continue

Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ARPO
CIK: 1422142
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-017966
Submitted to the SEC: Thu May 09 2019 4:06:39 PM EST
Accepted by the SEC: Thu May 09 2019
Period: Sunday, March 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/arpo/0001564590-19-017966.htm

Aerpio Pharmaceuticals, Inc. (ARPO) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

SEC Filings

ARPO Valuations

ARPO Annual Reports

ARPO Quarterly Reports

ARPO Corporate News